A photo of Luke Smart.

Luke R. Smart, MD

  • Assistant Professor, UC Department of Pediatrics
  • UC Department of Internal Medicine



My clinical specialty is non-malignant hematological conditions, especially those that affect patients across the life span. I completed a dual residency training in internal medicine and pediatrics and a dual fellowship training in pediatric hematology/oncology and adult hematology. In my practice, I see patients at Cincinnati Children's and the University of Cincinnati (UC). I am the director of the adult sickle cell clinic at UC.

I enjoy working with patients across the age-span and with their family members, whether they are the parents of a pediatric patient or the children of an adult patient. I like educating patients so they understand how the healthcare system functions, how their disease works and how to advocate for themselves. I enjoy answering difficult questions and working with a team of people to provide the optimal care that I could not achieve alone.

My research interest is hematological conditions in low-resource settings, especially sickle cell disease in sub-Saharan Africa. I have described the epidemiology of diseases, investigated new diagnostic tests and studied the best way to treat these diseases in sub-Saharan Africa. I became interested in this work when I completed a four-year global health fellowship under Weill Cornell Medicine. I spent those years living in Tanzania at a referral and teaching hospital, working as a clinician, educator and researcher. I saw that hematological disease in general, and sickle cell disease specifically, were prevalent and painful conditions that often led to hospitalization and death. I enjoyed working with local faculty who focused on treatments for hematological disorders. Overall, my goal is to improve the lives of people with hematological diseases, especially sickle cell disease, in low-resource settings.

I have been privileged to participate in two American Society of Hematology training programs. I was a recipient of a Research Training Award for Fellows in my final year of fellowship and was accepted into the Clinical Research Training Institute as a junior faculty. Both of these are tremendous honors and they provided significant support for my early research career.

During my fellowship, I also received a Thrasher Foundation early career award that allowed me to investigate a novel color-based point-of-care diagnostic device for anemia in Africa. Performing clinical research in low-resource settings can be challenging. Still, it's essential that we conduct research where people, especially children, are most affected by disease to improve children's lives around the world.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE): a Phase 2 primary stroke prevention trial in sub-Saharan Africa. Smart, LR; Ambrose, EE; Balyorugulu, G; Songoro, P; Shabani, I; Komba, P; Charles, M; Howard, TA; McElhinney, KE; O'Hara, SM; et al. Acta Haematologica. 2022.

Health Related Quality of Life among Children with Sickle Cell Anaemia in Northwestern Tanzania. Mwazyunga, Z; Ambrose, EE; Kayange, N; Bakalemwa, R; Kidenya, B; Smart, LR; Hokororo, A. 2022; 12:11-28.

Pediatric Hydrocephalus in Northwest Tanzania: A Descriptive Cross-Sectional Study of Clinical Characteristics and Early Surgical Outcomes from the Bugando Medical Centre. Aukrust, CG; Parikh, K; Smart, LR; Mdala, I; Fjeld, HE; Lubuulwa, J; Makene, AM; Härtl, R; Winkler, AS. World Neurosurgery. 2022; 161:e339-e346.

Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. British Journal of Haematology. 2021; 194:617-625.

Newborn screening for sickle cell disease in sub-Saharan Africa: Is the glass half-full yet?. Smart, LR; Ware, RE. Pediatric Blood and Cancer. 2021; 68.

Linkage to Care Intervention to Improve Post-Hospital Outcomes Among Children with Sickle Cell Disease in Tanzania: A Pilot Study. Hau, DK; Ambrose, EE; Smart, LR; Kayange, NM; Peck, RN. Journal of Pediatrics. 2021; 232:290-293.e1.

AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. Perez-Plazola, MS; Tyburski, EA; Smart, LR; Howard, TA; Pfeiffer, A; Ware, RE; Lam, WA; McGann, PT. BMC Medicine. 2020; 18.

Surveillance for sickle cell disease, United Republic of Tanzania. Ambrose, EE; Smart, LR; Charles, M; Hernandez, AG; Latham, T; Hokororo, A; Beyanga, M; Howard, TA; Kamugisha, E; McElhinney, KE; et al. Bulletin of the World Health Organization. 2020; 98:859-868.

FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Brown, RC; Cruz, K; Kalfa, TA; Kuypers, FA; Saraf, SL; Estepp, JH; Smart, LR; Malik, P; Lerman, M; Mayer, R; et al. Blood. 2020; 136:19-20.

Extremely high birth prevalence of sickle cell disease in rural Tanzania. Eastburg, L; Peckham, A; Kawira, E; Chirangi, B; Adler, D; Akungo, BD; Smart, LR; Ambrose, EE. Pediatric Blood and Cancer. 2020; 67.

From the Blog

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey